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Abstract Mortality from stomach cancer has fallen
steadily during the past decades. The aim of this paper is to
assess the implication of a possible continuation of the
decline in stomach cancer mortality until the year 2030.
Annual rates of decline in stomach cancer mortality from
1980 to 2005 were determined for the Netherlands, United
Kingdom, France, and four Nordic countries on the basis of
regression analysis. Mortality rates were extrapolated until
2030, assuming the same rate of decline as in the past,
using three possible scenarios. The absolute numbers of
deaths were projected taking into account data on the
ageing of national populations. Stomach cancer mortality
rates declined between 1980 and 2005 at about the same
rate (3.6–4.9% per year) for both men and women in all
countries. The rate of decline did not level off in recent
years, and it was not smaller in countries with lower overall
mortality rates in 1980. If this decline were to continue into
the future, stomach cancer mortality rates would decline
with about 66% between 2005 and 2030 in most
populations, while the absolute number of stomach cancer
deaths would diminish by about 50%. Thus, in view of the
strong, stable and consistent mortality declines in recent
decades, and despite population ageing, stomach cancer is
likely to become far less important as a cause of death in
Europe in the future.
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Introduction
Stomach cancer is the fourth most frequent cancer [1, 2]
and the world’s second leading cause of cancer mortality
[1]. However, it has been fallen throughout Europe during
the past decades in terms of both incidence and mortality
rates [3, 4], mainly as a result of remarkable improvement
of living conditions in European societies [5–8]. Efforts to
reduce global cancer disparities begin with an under-
standing of geographic patterns in cancer incidence, mor-
tality and prevalence, by studies such as GLOBOCAN [9,
10], EUROCARE [11], and Five Continents databases [12].
Survival increased and mortality decreased through the
combination of earlier detection, better access to care and
improved treatment [13]. There has also been a concomi-
tant change in lifestyle and environmental exposures over
successive generations [14], including changes in expo-
sures to risk factors in early life [15].
Several studies conducted projections of future trends in
stomach cancer mortality in European countries [7, 12,
14–17]. Mortality rates were generally expected to decline
further. Based on the cancer mortality trends in the Euro-
pean Union until 2000, one study projected a further fall by
11% in age-standardized cancer mortality from 2000 to
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2015 [16]. A Dutch study also projected a substantial
decline in stomach cancer mortality until 2015, based on
trends until 2000 [17]. Similarly, an Irish study predicted
mortality from stomach cancer to fall further in the near
future, although at a slower rate than in the recent past [18].
European studies included projections of the absolute
number of cancer deaths, thereby taking into account the
rapid ageing of European populations in the forthcoming
decades [14–16]. Population ageing alone may induce a
strong increase in the absolute number of incident cases
and deaths for many types of cancer. However, in the case
of stomach cancer, this demographic effect may be offset
by an opposite epidemiological effect if the recent decline
in age-specific mortality rates were to continue in the
future.
The aim of this study was to assess, for seven European
countries, the implications of a possible continuation of the
recent declines in stomach cancer rates. Future trends were
evaluated in terms of not only mortality rates, but also
absolute numbers of death, thereby taking into account the
ageing of national populations.
Projections of future mortality trends should be based on
a careful analysis of trends in the past [19, 20]. We
therefore started the analysis with a description of trends in
stomach cancer mortality over a long period, from 1980 up
to 2005, in order to check whether mortality declines
continued undiminished until recent years. In addition, we
assessed whether the rate of decline was similar for all
seven countries and both sexes, despite differences in
overall levels of stomach mortality rates. We thus aimed to
identify a stable and consistent long-term mortality trend
that could serve as a basis for projections into the future. In
addition, we formulated three scenarios to express uncer-
tainties regarding future mortality trends.
Materials and methods
Data for Denmark, Finland, France metropolitan, the
Netherlands, Norway, Sweden and England and Wales on
the number of deaths from stomach cancer (ICD code 151
for ICD-8 and ICD-9, C16 for ICD-10 [21]) and corre-
sponding numbers of population at risk, by sex and five-
year age groups for the years 1980–2005 have been
obtained from Eurostat (Denmark from 1999 to 2001,
France from 1998–2005, and other countries from 2000 to
2005) and national data sources (1980–1999) [22]. The
historical national data for England and Wales and France
were transformed into data for United Kingdom and France
metropolitan, by applying age and sex-specific correction
factors, based on the comparison of stomach cancer mor-
tality rates in 1995.
To describe trends in stomach cancer mortality between
1980 and 2005, sex-specific age-standardized mortality
rates were calculated using direct standardization, taking
the average national male and female populations by 5 year
age groups over 2000–2005 (2000–2001 for Denmark) as
the standard populations. In addition, we estimated sex-
and country- specific annual mortality changes (%) over
the period 1980–2005 by means of age-period log-linear
regression analysis. The dependent variable was the num-
ber of deaths, with the person-years at risk (estimated by
the midyear population) as offset variable. We used age by
5 year age groups (from 0 to 80 ?) (categorical) and single
calendar year (continuous) as independent variables.
Annual mortality changes (%) were calculated by this
formula: 100*(exp(b)-1), in which b is the parameter esti-
mate of the calendar year variable.
To project age, sex, and country-specific mortality rates
until 2030, we assumed that the mortality trends in the past
25 years (from 1980 to 2005) would continue for the
coming 25 years. Therefore, we applied the estimated
annual changes in mortality in the period 1980–2005 for all
age groups combined to average national age-specific
mortality rates in 2000–2005.
To express uncertainties regarding future mortality
trends, we formulated three scenarios. In the reference
scenario, the future rate of change was assumed to be equal
for all countries and therefore was calculated as the
unweighted average of the rates of change of the seven
countries. In the pessimistic scenario, we assumed the
future rate of change to be equal to the slowest observed
rate of change observed among all countries. In the opti-
mistic scenario, we took the highest rate of change
observed in the past. All three scenarios distinguished men
and women.
The formula used to make projections, per country and
sex, was: nM
t0þt
x ¼ nMt0x  ðncx þ 1Þt, where M denotes the
mortality rate in the age interval x to x ? n. De year t is
expressed as the difference with the baseline year t0
(= 2005); thus t = 25 for the year 2030. The change factor
c* is the observed annual decline (exp(b)-1) for all age
groups combined, multiplied by a ratio expressing the
annual decline in the age groups 40–59, 60–79, and
80 ? relative to the annual decline for all age groups
(unweighted average over all countries). In the reference
scenario, the applied ratios for men were 0.92, 1.03, and
0.99 for the age groups 40–59, 60–79, and 80 and more,
respectively; and the ratios for women were 0.85, 0.97, and
1.09, respectively.
Future stomach cancer mortality numbers were esti-
mated by applying the future sex and age-specific rates to
the projected age-specific population sizes for the different
countries up to 2030. These future population numbers
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have been obtained from Eurostat (baseline variant), except
for Norway for which the data have been obtained from
Statistics Norway (medium national Growth variant)
(http://statbank.ssb.no/statistikkbanken). Looking into the
projected mortality rates and absolute number of deaths in
2030, it can be measured if stomach cancer is a less
important cause of death in the future.
Results
Figure 1 shows trends in age-standardized mortality rates
between 1980 and 2005. In all countries, stomach cancer
mortality rates declined steadily. The rate of decline is
within a narrow range, from 3.61% per year for Norwegian
men to 4.90% for Danish and Finnish women. The overall
average rate of decline was 4.2% per year. The rate of
decline remained similar over time for both sexes in most
of these countries. There was no indication that the rate of
decline (expressed in percent decline per year) had been
levelling off in recent years. A main exception is the strong
decline in mortality among Finnish women in the 1980s,
when Finnish women were catching up with other
countries.
In Fig. 2, the rate of declines in stomach cancer mor-
tality over the period 1980–2005 is plotted against the age-
standardized mortality rates in 1980. The aim of this scatter
plot is to assess whether the decline in stomach cancer
mortality was higher in populations with higher initial
mortality rates. However, both among men and women, no
such positive association was found.
Table 1 presents projections for 2030 of stomach cancer
mortality rates. Values projected for 2030 are compared to
values observed for 2005 by means of ratios with 2005 as
reference. In all seven European countries, age-standard-
ized mortality rates would have declined in 2030 compared
to 2005 if past trends were to continue. This decline would
be substantial in all populations. The average decline in
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Fig. 1 Age-standardized
stomach cancer mortality rates
(per 100,000) in seven European
countries by sex: 1980–2005
Corresponding estimates of
annual declines (%) for men
(women) are for Denmark 4.60
(4.90), United Kingdom 3.96
(4.16), Finland 4.68 (4.90),
France Metropolitan 3.67
(4.32), Netherlands 3.92 (3.81),
Norway 3.61 (3.90), and
Sweden 4.06 (4.11)
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mortality rates over the period 2005–2030 would for men
amount to 66%, 59% and 75% for the reference, pessi-
mistic, and optimistic scenarios, respectively. For women
this would amount to 67%, 59% and 77% respectively.
Table 2 presents projections for 2030 of the absolute
number of stomach cancer deaths. Values projected for
2030 are compared to values observed for 2005 by means
of ratios with 2005 as reference. The decline in the absolute
number of deaths would be substantial as well, although
with more variability between countries. The average
decline in deaths over the period 2005–2030 would for men
amount to 43%, 32% and 59% for the reference, pessi-
mistic, and optimistic scenarios, respectively. For women
this would amount to 54%, 42% and 67% respectively.
Discussion
The strong decline in stomach cancer mortality was found
to continue at an undiminished rate until 2005 in each of
the seven European countries. If this decline were to con-
tinue into the future, stomach cancer mortality rates would
decline with about 66% between 2005 and 2030. The
absolute number of stomach cancer deaths would diminish
by about 50% despite the ageing of national populations.
Even though weaker declines were predicted in the pessi-
mistic scenario, this scenario as well implied that stomach
cancer would become far less important as a cause of death
in Europe in the next decades.
A key factor for the past declines in stomach cancer
mortality is a decrease in the exposure to Helicobacter
pylori (H. pylori) infection [23]. H. pylori prevalence had
been found to decline in parallel with the decrease of
incidence of stomach cancer [24]. However, H. Pylori
infection may not be the only factor. It has been estimated
to account for only half of the global total burden of
stomach cancer because of synergistic or antagonistic roles
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Table 1 Stomach cancer mortality rates (age standardized, per 100,000), by scenario, country and sex, for 2005 (observed) and 2030 (projected)
Year Country
Denmark United Kingdom Finland France Netherlands Norway Sweden
Men
Reference 2005 7.40 12.95 11.09 9.87 11.40 10.37 10.27
2030 2.62 4.22 3.80 3.39 3.84 3.74 3.48
Scenario 2030/2005a 0.35 0.33 0.34 0.34 0.34 0.36 0.34
Pessimistic 2030 3.21 5.06 4.60 4.10 4.62 4.52 4.21
Scenario 2030/2005a 0.43 0.39 0.41 0.41 0.41 0.44 0.41
Optimistic 2030 1.87 3.08 2.78 2.47 2.80 2.71 2.52
Scenario 2030/2005a 0.25 0.24 0.25 0.25 0.25 0.26 0.24
Women
Reference 2005 4.73 8.02 8.69 5.49 6.70 8.44 6.22
2030 1.59 2.34 2.91 1.81 2.32 2.39 2.29
Scenario 2030/2005a 0.34 0.29 0.34 0.33 0.35 0.28 0.37
Pessimistic 2030 2.00 2.90 3.62 2.26 2.89 2.99 2.85
Scenario 2030/2005a 0.42 0.36 0.42 0.41 0.43 0.35 0.46
Optimistic 2030 1.14 1.68 2.13 1.28 1.69 1.71 1.65
Scenario 2030/2005a 0.24 0.21 0.24 0.23 0.25 0.20 0.27
For Denmark, the values for 2005 are not observed but projected
Reference scenario = Equal future rate of change for all countries; Pessimistic scenario = Slowest observed rate of change for all countries;
Optimistic scenario = Highest rate of change for all countries
a The figure for 2030 divided by the related figure for 2005
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of dietary and other exogenous factors [25]. Complemen-
tary explanations for the observed declines in stomach
cancer mortality may include better food preservation and
refrigeration, improvement in environmental conditions
and lifestyle changes [26, 27]. Similarly, declines in the
near future may still be largely driven by recent improve-
ments in the living conditions that current generations had
experienced during their childhood and adulthood.
Improved medical treatment may also have contributed
to the decline in mortality from stomach cancer [26, 27]
like it contributed to the observed differences in stomach
cancer mortality between European countries [27]. There-
fore, further advances in the treatment for stomach cancer
and H. pylori infections may be important to maintain a
strong decline in stomach cancer mortality rates in the
future. This role is supported by the observation that, while
the incidence of stomach cancer had declined as well,
mortality rates seemed to have declined at faster rates,
indicating a decline in case fatality rates [14]. However, we
should note that different trends in incidence and mortality
of cancer are found for most solid tumours, and may be a
consequence of increased detection of early tumours with
often good prognosis [28].
Empirical support for the expectation that the decline in
mortality from stomach cancer will continue in the future
comes from the trends that were observed for the past
25 years. Firstly, there is a strong consistency in the recent
trends in stomach cancer mortality among both sexes and
among each of the seven European countries. Second, these
declines had persisted up to recent years in each of these
populations, including those with the lowest initial mor-
tality rates. Furthermore, steady declines in stomach cancer
mortality were observed in the middle-aged and the young
population as well, suggesting that they are likely to con-
tinue in the near future [4, 5, 16]. The latter observation is
consistent with observations of cohort-wise patterns of
decline in stomach cancer mortality in European countries
[14, 29, 30], which may reflect the effects of improvement
in living conditions in childhood [29].
It should be emphasized that, even though future declines
may seem likely, our study was primarily aimed at exploring
possible future trends by extrapolating past trends. This
extrapolation provides a baseline scenario against which new
studies may formulate more specific scenarios of future
trends. For example, policy-based scenarios may focus on
the potential effects of specific preventive policies or
advancement in the treatment of stomach cancer. As stomach
cancer may become ever less important in terms of mortality,
scenario studies will need to also include measures of inci-
dence, prognosis and prevalence of stomach cancer.
Table 2 Stomach cancer absolute numbers of deaths, by scenario, country and sex, for 2005 (observed) and 2030 (projected)
Year Country
Denmark United Kingdom Finland France Netherlands Norway Sweden
Men
Reference 2005 209 3914 301 3045 963 242 470
2030 112 2050 186 1675 556 155 240
Scenario 2030/2005a 0.54 0.52 0.62 0.55 0.58 0.64 0.51
Pessimistic 2030 137 2467 225 2090 667 186 291
Scenario 2030/2005a 0.66 0.63 0.75 0.67 0.69 0.77 0.62
Optimistic 2030 79 1480 133 1204 404 111 172
Scenario 2030/2005a 0.38 0.38 0.44 0.40 0.42 0.46 0.37
Women
Reference 2005 131 2475 240 1789 566 196 284
2030 58 1021 119 877 290 81 138
Scenario 2030/2005a 0.44 0.41 0.50 0.49 0.51 0.41 0.49
Pessimistic 2030 73 1266 148 1100 360 101 171
Scenario 2030/2005a 0.56 0.51 0.62 0.62 0.64 0.51 0.60
Optimistic 2030 41 725 84 606 209 58 98
Scenario 2030/2005a 0.32 0.29 0.35 0.34 0.37 0.30 0.35
For Denmark, the values for 2005 are not observed but projected
Reference scenario = Equal future rate of change for all countries; Pessimistic scenario = Slowest observed rate of change for all countries;
Optimistic scenario = Highest rate of change for all countries
a The figure for 2030 divided by the related figure for 2005
The decline in stomach cancer mortality 27
123
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J
Gastroenterol. 2006;12(3):354–62.
2. Prinz C, Schwendy S, Voland P. H pylori and gastric cancer:
shifting the global burden. World J Gastroenterol. 2006;12(34):
5458–64.
3. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk
factors. J Clin Epidemiol. 2003;56(1):1–9.
4. Levi F, Lucchini F, Gonzalez JR, Fernandez E, Negri E, La
Vecchia C. Monitoring falls in gastric cancer mortality in Europe.
Ann Oncol. 2004;15(2):338–45.
5. Bosetti C, Bertuccio P, Levi F, Lucchini F, Negri E, La Vecchia
C. Cancer mortality in the European Union, 1970–2003, with a
joinpoint analysis. Ann Oncol. 2008;19(4):631–40.
6. Lepage C, Remontet L, Launoy G, et al. Trends in incidence of
digestive cancers in France. Eur J Cancer Prev. 2008;17(1):13–7.
7. Levi F, Lucchini F, Negri E, La Vecchia C. Continuing declines
in cancer mortality in the European Union. Ann Oncol. 2007;
18(3):593–5.
8. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer
statistics, 2007. CA Cancer J Clin. 2007;57(1):43–66.
9. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world
cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153–6.
10. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics,
2002. CA Cancer J Clin. 2005;55(2):74–108.
11. Francisci S, Capocaccia R, Grande E, et al. The cure of cancer: a
European perspective. Eur J Cancer. 2009;45(6):1067–79.
12. Kamangar F, Dores GM, Anderson WF. Patterns of cancer inci-
dence, mortality, and prevalence across five continents: defining
priorities to reduce cancer disparities in different geographic
regions of the world. J Clin Oncol. 2006;24(14):2137–50.
13. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Sie-
sling S, Coebergh JW. Recent trends of cancer in Europe: a
combined approach of incidence, survival and mortality for 17
cancer sites since the 1990s. Eur J Cancer. 2008;44(10):1345–89.
14. Fitzsimmons D, Osmond C, George S, Johnson CD. Trends in
stomach and pancreatic cancer incidence and mortality in Eng-
land and Wales, 1951–2000. Br J Surg. 2007;94(9):1162–71.
15. Aragones N, Pollan M, Rodero I, Lopez-Abente G. Gastric cancer
in the European Union (1968–1992): mortality trends and cohort
effect. Ann Epidemiol. 1997;7(4):294–303.
16. Quinn MJ, d’Onofrio A, Moller B, et al. Cancer mortality trends
in the EU and acceding countries up to 2015. Ann Oncol. 2003;
14(7):1148–52.
17. Coebergh JW. Kanker in Nederland: KWF kankerbestrijding;
2004: 88–94. Avalable from http://spitswww.uvt.nl/*Fmols/
kanker_in_nederland.pdf.
18. O’Lorcain P, Deady S, Comber H. Mortality predictions for
esophageal, stomach, and pancreatic cancer, Ireland, up to 2015.
Int J Gastrointest Cancer. 2006;37(1):15–25.
19. Janssen F, Kunst A. The choice among past trends as a basis for
the prediction of future trends in old-age mortality. Popul Stud
(Camb). 2007;61(3):315–26.
20. Wilmoth JR. Demography of longevity: past, present, and future
trends. Exp Gerontol. 2000;35(9–10):1111–29.
21. Janssen F, Kunst AE. ICD coding changes and discontinuities in
trends in cause-specific mortality in six European countries,
1950–99. Bull World Health Organ. 2004;82(12):904–13.
22. Janssen F, Mackenbach JP, Kunst AE. Trends in old-age mor-
tality in seven European countries, 1950–1999. J Clin Epidemiol.
2004;57(2):203–16.
23. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P.
Estimates of the cancer incidence and mortality in Europe in
2006. Ann Oncol. 2007;18(3):581–92.
24. Axon A. Helicobacter pylori: what do we still need to know? J
Clin Gastroenterol. 2006;40(1):15–9.
25. Key TJ, Schatzkin A, Willett WC, Allen NE, Spencer EA, Travis
RC. Diet, nutrition and the prevention of cancer. Public Health
Nutr. 2004;7(1A):187–200.
26. Corley DA, Kubo A. Influence of site classification on cancer
incidence rates: an analysis of gastric cardia carcinomas. J Natl
Cancer Inst. 2004;96(18):1383–7.
27. Verdecchia A, Corazziari I, Gatta G, Lisi D, Faivre J, Forman D.
Explaining gastric cancer survival differences among European
countries. Int J Cancer. 2004;109(5):737–41.
28. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer
incidence and mortality in Europe in 2008. Eur J Cancer.
2010;46(4):765–81.
29. Amiri M, Kunst AE, Janssen F, Mackenbach JP. Trends in
stomach cancer mortality in relation to living conditions in
childhood. A study among cohorts born between 1860 and 1939
in seven European countries. Eur J Cancer. 2006;42(18):3212–8.
30. La Vecchia C, Negri E, Levi F, Decarli A, Boyle P. Cancer
mortality in Europe: effects of age, cohort of birth and period of
death. Eur J Cancer. 1998;34(1):118–41.
28 M. Amiri et al.
123
